NASDAQ:VICL - Vical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.19 +0.03 (+2.59 %)
(As of 03/20/2019 04:00 PM ET)
Previous Close$1.16
Today's Range$1.18 - $1.19
52-Week Range$0.85 - $1.82
Volume71,935 shs
Average Volume371,615 shs
Market Capitalization$25.97 million
P/E Ratio-1.47
Dividend YieldN/A
Beta0.53
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection. Vical Incorporated has a license agreement with Astellas Pharma Inc. to develop and commercialize VL-2397 antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

Receive VICL News and Ratings via Email

Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VICL
CUSIP92560210
Phone858-646-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.62 million
Book Value$2.24 per share

Profitability

Net Income$-16,250,000.00
Net Margins-1,002.10%

Miscellaneous

EmployeesN/A
Market Cap$25.97 million
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Vical (NASDAQ:VICL) Frequently Asked Questions

What is Vical's stock symbol?

Vical trades on the NASDAQ under the ticker symbol "VICL."

How were Vical's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) issued its quarterly earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.17) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.17). The biotechnology company earned $0.12 million during the quarter, compared to the consensus estimate of $0.04 million. Vical had a negative return on equity of 33.58% and a negative net margin of 1,002.10%. View Vical's Earnings History.

When is Vical's next earnings date?

Vical is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Vical.

What price target have analysts set for VICL?

2 Wall Street analysts have issued twelve-month price objectives for Vical's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Vical's stock price to reach $4.00 in the next year. This suggests a possible upside of 236.1% from the stock's current price. View Analyst Price Targets for Vical.

What is the consensus analysts' recommendation for Vical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vical in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vical.

Has Vical been receiving favorable news coverage?

Media coverage about VICL stock has trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vical earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days.

Who are some of Vical's key competitors?

What other stocks do shareholders of Vical own?

Who are Vical's key executives?

Vical's management team includes the folowing people:
  • Mr. Vijay B. Samant, CEO, Pres & Director (Age 66)
  • Mr. Anthony Alan Ramos, VP, CFO & Chief Accounting Officer (Age 52)
  • Dr. Lawrence Russell Smith, Sr. VP of Research (Age 58)
  • Dr. Mammen P. Mammen Jr., Sr. VP of Clinical Devel. (Age 55)

Who are Vical's major shareholders?

Vical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Two Sigma Investments LP (0.14%). Company insiders that own Vical stock include Anthony Alan Ramos, Armistice Capital Master Fund, Armistice Capital, Llc and Robert C Merton. View Institutional Ownership Trends for Vical.

Which institutional investors are selling Vical stock?

VICL stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP. View Insider Buying and Selling for Vical.

How do I buy shares of Vical?

Shares of VICL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vical's stock price today?

One share of VICL stock can currently be purchased for approximately $1.19.

How big of a company is Vical?

Vical has a market capitalization of $25.97 million and generates $1.62 million in revenue each year. The biotechnology company earns $-16,250,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

What is Vical's official website?

The official website for Vical is http://www.vical.com.

How can I contact Vical?

Vical's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at www.vical.com.


MarketBeat Community Rating for Vical (NASDAQ VICL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Vical and other stocks. Vote "Outperform" if you believe VICL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VICL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Featured Article: Net Asset Value

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel